PTC124 for Nonsense Mutations

kitomd21

New member
PTC Announces Data Showing That PTC124 Causes Statistically Significant
Improvements in Chloride Channel Function in Cystic Fibrosis Patients

I don't have the exact data as this was taken from an email update I signed up for....

PTC124 Highlighted in Multiple Presentations at North American Cystic Fibrosis Conference -

South Plainfield, NJ and Orlando, FL - October 24, 2008 - PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle Sermet-Gaudelus, M.D., Ph.D., principal investigator at l'Hôpital Necker-Enfants Malades. In addition, results from an Israeli Phase 2a study demonstrated statistically significant improvements in the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein and a statistically significant decrease in the frequency of cough, one of the most prominent and burdensome CF-related symptoms. Data from the Israeli study were presented by Eitan Kerem, M.D., principal investigator and head of the department of pediatrics and Cystic Fibrosis Center at Hadassah University Hospital.
 

kitomd21

New member
PTC Announces Data Showing That PTC124 Causes Statistically Significant
Improvements in Chloride Channel Function in Cystic Fibrosis Patients

I don't have the exact data as this was taken from an email update I signed up for....

PTC124 Highlighted in Multiple Presentations at North American Cystic Fibrosis Conference -

South Plainfield, NJ and Orlando, FL - October 24, 2008 - PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle Sermet-Gaudelus, M.D., Ph.D., principal investigator at l'Hôpital Necker-Enfants Malades. In addition, results from an Israeli Phase 2a study demonstrated statistically significant improvements in the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein and a statistically significant decrease in the frequency of cough, one of the most prominent and burdensome CF-related symptoms. Data from the Israeli study were presented by Eitan Kerem, M.D., principal investigator and head of the department of pediatrics and Cystic Fibrosis Center at Hadassah University Hospital.
 

kitomd21

New member
PTC Announces Data Showing That PTC124 Causes Statistically Significant
Improvements in Chloride Channel Function in Cystic Fibrosis Patients

I don't have the exact data as this was taken from an email update I signed up for....

PTC124 Highlighted in Multiple Presentations at North American Cystic Fibrosis Conference -

South Plainfield, NJ and Orlando, FL - October 24, 2008 - PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle Sermet-Gaudelus, M.D., Ph.D., principal investigator at l'Hôpital Necker-Enfants Malades. In addition, results from an Israeli Phase 2a study demonstrated statistically significant improvements in the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein and a statistically significant decrease in the frequency of cough, one of the most prominent and burdensome CF-related symptoms. Data from the Israeli study were presented by Eitan Kerem, M.D., principal investigator and head of the department of pediatrics and Cystic Fibrosis Center at Hadassah University Hospital.
 

kitomd21

New member
PTC Announces Data Showing That PTC124 Causes Statistically Significant
Improvements in Chloride Channel Function in Cystic Fibrosis Patients

I don't have the exact data as this was taken from an email update I signed up for....

PTC124 Highlighted in Multiple Presentations at North American Cystic Fibrosis Conference -

South Plainfield, NJ and Orlando, FL - October 24, 2008 - PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle Sermet-Gaudelus, M.D., Ph.D., principal investigator at l'Hôpital Necker-Enfants Malades. In addition, results from an Israeli Phase 2a study demonstrated statistically significant improvements in the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein and a statistically significant decrease in the frequency of cough, one of the most prominent and burdensome CF-related symptoms. Data from the Israeli study were presented by Eitan Kerem, M.D., principal investigator and head of the department of pediatrics and Cystic Fibrosis Center at Hadassah University Hospital.
 

kitomd21

New member
<br />PTC Announces Data Showing That PTC124 Causes Statistically Significant
<br /> Improvements in Chloride Channel Function in Cystic Fibrosis Patients
<br />
<br />I don't have the exact data as this was taken from an email update I signed up for....
<br />
<br />PTC124 Highlighted in Multiple Presentations at North American Cystic Fibrosis Conference -
<br />
<br />South Plainfield, NJ and Orlando, FL - October 24, 2008 - PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle Sermet-Gaudelus, M.D., Ph.D., principal investigator at l'Hôpital Necker-Enfants Malades. In addition, results from an Israeli Phase 2a study demonstrated statistically significant improvements in the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein and a statistically significant decrease in the frequency of cough, one of the most prominent and burdensome CF-related symptoms. Data from the Israeli study were presented by Eitan Kerem, M.D., principal investigator and head of the department of pediatrics and Cystic Fibrosis Center at Hadassah University Hospital.
<br />
 

Diane

New member
This is good news....Thanks for sharing <img src="i/expressions/face-icon-small-smile.gif" border="0">
 

Diane

New member
This is good news....Thanks for sharing <img src="i/expressions/face-icon-small-smile.gif" border="0">
 

Diane

New member
This is good news....Thanks for sharing <img src="i/expressions/face-icon-small-smile.gif" border="0">
 

Diane

New member
This is good news....Thanks for sharing <img src="i/expressions/face-icon-small-smile.gif" border="0">
 

Diane

New member
This is good news....Thanks for sharing <img src="i/expressions/face-icon-small-smile.gif" border="0">
 
Top